Puma Biotechnology Inc (PBYI) : Bogle Investment Management L P De scooped up 234,672 additional shares in Puma Biotechnology Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 395,750 shares of Puma Biotechnology Inc which is valued at $19,245,323.Puma Biotechnology Inc makes up approximately 1.21% of Bogle Investment Management L P De’s portfolio.
Other Hedge Funds, Including , Blackrock Japan Ltd added PBYI to its portfolio by purchasing 37 company shares during the most recent quarter which is valued at $1,799.State Board Of Administration Of Florida Retirement System reduced its stake in PBYI by selling 8,796 shares or 33.94% in the most recent quarter. The Hedge Fund company now holds 17,123 shares of PBYI which is valued at $826,870.Cornerstone Capital Management reduced its stake in PBYI by selling 126,492 shares or 20.76% in the most recent quarter. The Hedge Fund company now holds 482,707 shares of PBYI which is valued at $23,309,921. Puma Biotechnology Inc makes up approx 1.16% of Cornerstone Capital Management’s portfolio.
Puma Biotechnology Inc opened for trading at $57.69 and hit $59.61 on the upside on Monday, eventually ending the session at $59.12, with a gain of 2.59% or 1.49 points. The heightened volatility saw the trading volume jump to 4,73,938 shares. Company has a market cap of $1,921 M.
Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.